Literature DB >> 23610399

Strength of PD-1 signaling differentially affects T-cell effector functions.

Fang Wei1, Shi Zhong, Zhengyu Ma, Hong Kong, Andrew Medvec, Rafi Ahmed, Gordon J Freeman, Michelle Krogsgaard, James L Riley.   

Abstract

High surface expression of programmed death 1 (PD-1) is associated with T-cell exhaustion; however, the relationship between PD-1 expression and T-cell dysfunction has not been delineated. We developed a model to study PD-1 signaling in primary human T cells to study how PD-1 expression affected T-cell function. By determining the number of T-cell receptor/peptide-MHC complexes needed to initiate a Ca(2+) flux, we found that PD-1 ligation dramatically shifts the dose-response curve, making T cells much less sensitive to T-cell receptor-generated signals. Importantly, other T-cell functions were differentially sensitive to PD-1 expression. We observed that high levels of PD-1 expression were required to inhibit macrophage inflammatory protein 1 beta production, lower levels were required to block cytotoxicity and IFN-γ production, and very low levels of PD-1 expression could inhibit TNF-α and IL-2 production as well as T-cell expansion. These findings provide insight into the role of PD-1 expression in enforcing T-cell exhaustion and the therapeutic potential of PD-1 blockade.

Entities:  

Keywords:  HIV-1 specific T cell response; TCR signaling; peptide counting

Mesh:

Substances:

Year:  2013        PMID: 23610399      PMCID: PMC3703988          DOI: 10.1073/pnas.1305394110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  62 in total

1.  PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine.

Authors:  T Okazaki; A Maeda; H Nishimura; T Kurosaki; T Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-06       Impact factor: 11.205

2.  CD4 enhances T cell sensitivity to antigen by coordinating Lck accumulation at the immunological synapse.

Authors:  Qi-Jing Li; Aaron R Dinner; Shuyan Qi; Darrell J Irvine; Johannes B Huppa; Mark M Davis; Arup K Chakraborty
Journal:  Nat Immunol       Date:  2004-07-11       Impact factor: 25.606

3.  Structural and functional analysis of the costimulatory receptor programmed death-1.

Authors:  Xuewu Zhang; Jean-Claude D Schwartz; Xiaoling Guo; Sumeena Bhatia; Erhu Cao; Michael Lorenz; Michael Cammer; Lieping Chen; Zhong-Yin Zhang; Michael A Edidin; Stanley G Nathenson; Steven C Almo
Journal:  Immunity       Date:  2004-03       Impact factor: 31.745

4.  T cell killing does not require the formation of a stable mature immunological synapse.

Authors:  Marco A Purbhoo; Darrell J Irvine; Johannes B Huppa; Mark M Davis
Journal:  Nat Immunol       Date:  2004-03-28       Impact factor: 25.606

5.  The road to recovery: translating PD-1 biology into clinical benefit.

Authors:  James L Riley; Carl H June
Journal:  Trends Immunol       Date:  2006-12-22       Impact factor: 16.687

6.  Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression.

Authors:  Henry Radziewicz; Chris C Ibegbu; Marina L Fernandez; Kimberly A Workowski; Kamil Obideen; Mohammad Wehbi; Holly L Hanson; James P Steinberg; David Masopust; E John Wherry; John D Altman; Barry T Rouse; Gordon J Freeman; Rafi Ahmed; Arash Grakoui
Journal:  J Virol       Date:  2006-12-20       Impact factor: 5.103

7.  Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment.

Authors:  E John Wherry; Joseph N Blattman; Kaja Murali-Krishna; Robbert van der Most; Rafi Ahmed
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

8.  SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation.

Authors:  Jens M Chemnitz; Richard V Parry; Kim E Nichols; Carl H June; James L Riley
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

9.  The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo.

Authors:  Ian F Hermans; Jonathan D Silk; Jianping Yang; Michael J Palmowski; Uzi Gileadi; Corinna McCarthy; Mariolina Salio; Franca Ronchese; Vincenzo Cerundolo
Journal:  J Immunol Methods       Date:  2004-02-01       Impact factor: 2.303

10.  Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses.

Authors:  Frann Bennett; Deborah Luxenberg; Vincent Ling; I-Ming Wang; Kim Marquette; David Lowe; Nighat Khan; Geertruida Veldman; Kenneth A Jacobs; Viia E Valge-Archer; Mary Collins; Beatriz M Carreno
Journal:  J Immunol       Date:  2003-01-15       Impact factor: 5.422

View more
  133 in total

1.  PD-1/PD-L1 signal pathway participates in HCV F protein-induced T cell dysfunction in chronic HCV infection.

Authors:  Wen Xiao; Long Feng Jiang; Xiao Zhao Deng; Dan Yan Zhu; Jia Ping Pei; Mao Lei Xu; Bing Jun Li; Chang Jun Wang; Jing Hai Zhang; Qi Zhang; Zhen Xian Zhou; Wei Liang Ding; Xiao Dong Xu; Ming Yue
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

Review 2.  Inhibitors of the PD-1 Pathway in Tumor Therapy.

Authors:  Martin W LaFleur; Yuki Muroyama; Charles G Drake; Arlene H Sharpe
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

3.  Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma.

Authors:  Elly Marcq; Vasiliki Siozopoulou; Jorrit De Waele; Jonas van Audenaerde; Karen Zwaenepoel; Eva Santermans; Niel Hens; Patrick Pauwels; Jan P van Meerbeeck; Evelien L J Smits
Journal:  Oncoimmunology       Date:  2016-11-28       Impact factor: 8.110

4.  MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer.

Authors:  Mengyu Xie; Hong Zheng; Ranjna Madan-Lala; Wenjie Dai; Nicholas T Gimbrone; Zhihua Chen; Fumi Kinose; Sarah A Blackstone; Keiran S M Smalley; W Douglas Cress; Eric B Haura; Uwe Rix; Amer A Beg
Journal:  Cancer Res       Date:  2019-07-30       Impact factor: 12.701

5.  PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization.

Authors:  Brian T Rekoske; Heath A Smith; Brian M Olson; Brett B Maricque; Douglas G McNeel
Journal:  Cancer Immunol Res       Date:  2015-06-03       Impact factor: 11.151

6.  Early induction of interleukin-10 limits antigen-specific CD4⁺ T cell expansion, function, and secondary recall responses during persistent phagosomal infection.

Authors:  Abinav Kumar Singh; Nagaraja R Thirumalapura
Journal:  Infect Immun       Date:  2014-07-14       Impact factor: 3.441

7.  Differential Inhibitory Receptor Expression on T Cells Delineates Functional Capacities in Chronic Viral Infection.

Authors:  Jeffrey E Teigler; Gennadiy Zelinskyy; Michael A Eller; Diane L Bolton; Mary Marovich; Alexander D Gordon; Aljawharah Alrubayyi; Galit Alter; Merlin L Robb; Jeffrey N Martin; Steven G Deeks; Nelson L Michael; Ulf Dittmer; Hendrik Streeck
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

Review 8.  Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease.

Authors:  John Attanasio; E John Wherry
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

Review 9.  Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.

Authors:  Frank A Schildberg; Sarah R Klein; Gordon J Freeman; Arlene H Sharpe
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

10.  Programmed Death-1 Inhibition of Phosphatidylinositol 3-Kinase/AKT/Mechanistic Target of Rapamycin Signaling Impairs Sarcoidosis CD4+ T Cell Proliferation.

Authors:  Lindsay J Celada; Joseph E Rotsinger; Anjuli Young; Guzel Shaginurova; Debresha Shelton; Charlene Hawkins; Wonder P Drake
Journal:  Am J Respir Cell Mol Biol       Date:  2017-01       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.